*See appendix for listing of Steering Committee Members.
Chronic hepatitis B: treatment alert
Article first published online: 7 NOV 2006
Volume 26, Issue S2, pages 47–58, December 2006
How to Cite
ACT-HBV Asia-Pacific Steering Committee Members (2006), Chronic hepatitis B: treatment alert. Liver International, 26: 47–58. doi: 10.1111/j.1478-3231.2006.01374.x
- Issue published online: 7 NOV 2006
- Article first published online: 7 NOV 2006
- Received 26 May 2006,accepted 28 June 2006
- ALT levels;
- consensus statement;
- HBeAg negative;
- HBeAg positive;
- HBV DNA levels;
- treatment guidelines
Abstract: Chronic hepatitis B (CHB) is a serious global health concern, particularly in the Asia-Pacific region. New information on the clinical management of CHB is emerging rapidly, requiring that physicians be alerted to updated treatment recommendations. The ACT-HBV Asia-Pacific Steering Committee members, composed of experts in hepatitis B from throughout the Asia-Pacific region, reviewed and discussed new clinical data as reported in the literature or presented at recent international congresses, and recommended that physicians be alerted to updated treatment recommendations. Hepatitis B e antigen (HBeAg)-positive patients with HBV DNA levels of ≥20 000 IU/ml (≥105 copies/ml) and elevated alanine aminotransferase levels should be considered for treatment. It is suggested that HBV DNA≥2000 IU/ml (≥104 copies/ml) is the more appropriate threshold for the treatment of HBeAg-negative patients. Lamivudine, adefovir dipivoxil, interferon α-2b, thymosin α-1, and, most recently, entecavir, and pegylated interferon α-2a are licensed for the management of CHB. The treatment recommendations from the 2005 Asian-Pacific Consensus Statement on the Management of Chronic Hepatitis B have been updated to incorporate these new therapeutic options. A summary of treatment recommendations for special patient populations is also included.